Frank Hoentjen
Radboud University Nijmegen
Internal medicineRetrospective cohort studyTumor necrosis factor alphaProspective cohort studyAdverse effectCohort studyVedolizumabInfliximabInflammatory bowel diseaseDiscontinuationUstekinumabDiseaseCrohn's diseaseAdalimumabUlcerative colitisPopulationIn patientThiopurine methyltransferaseMedicineCohortGastroenterology
170Publications
16H-index
1,117Citations
Publications 169
Newest
#1Jurij Hanzel (Ljubljana University Medical Centre)H-Index: 5
#2Erwin Dreesen (Uppsala University)H-Index: 14
Last. Ron A. A. MathôtH-Index: 32
view all 10 authors...
BACKGROUND Higher serum concentrations of vedolizumab have been associated with improved outcomes in inflammatory bowel disease. It is unclear how vedolizumab exposure is linked to endoscopic remission in Crohn disease (CD). We aimed to develop a pharmacokinetic-pharmacodynamic model linking vedolizumab exposure to endoscopic remission in CD. METHODS Data were obtained from the first 110 patients participating in a phase 4 prospective multicenter trial (LOVE-CD; ClinicalTrials.gov identifier: NC...
Source
Abstract null null Background null Anti-TNFα is increasingly used as treatment for immune mediated inflammatory diseases (IMID), such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and psoriasis (PS). However, the impact of anti-TNFα during pregnancy on mother and newborn is under debate. This requires a sound knowledge of the effects of this treatment on pregnancy and neonatal outcomes. null null null Objectives null To assess pregnancy and neonatal outcomes after anti-TNFα ther...
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Tessa E H Römkens (Bosch)H-Index: 13
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 8 authors...
BACKGROUND Only limited data is available on the extent and burden of adverse drug reactions (ADRs) to biological therapy in inflammatory bowel disease (IBD) patients in daily practice, especially from a patient's perspective. OBJECTIVE The aim of this study was to systematically assess patient-reported ADRs during biological therapy in IBD patients and compare these with healthcare provider (HCP)-reported ADRs. METHODS This multicentre, prospective, event monitoring study enrolled IBD patients ...
Source
Source
Background: null Information on adverse drug reactions (ADRs) is generally clustered for all indications of a drug in the patient information leaflet. However, previous research has shown that participants of the Dutch Biologic Monitor (DBM) that use a biologic for their immune-mediated inflammatory disease (IMID) prefer to receive ADR information tailored to their own biologic an IMID (1). Currently, it is unclear whether the ADR profile of a specific biologic may differ between patients with d...
Source
Source
Source
Source
Source
Source